United Asset Strategies Inc. Acquires 5,950 Shares of Thermo Fisher Scientific Inc. $TMO

United Asset Strategies Inc. increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,161 shares of the medical research company’s stock after purchasing an additional 5,950 shares during the period. Thermo Fisher Scientific makes up 1.3% of United Asset Strategies Inc.’s portfolio, making the stock its 24th biggest position. United Asset Strategies Inc.’s holdings in Thermo Fisher Scientific were worth $15,599,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. TIAA Trust National Association boosted its holdings in Thermo Fisher Scientific by 10.5% in the second quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock valued at $50,256,000 after acquiring an additional 11,817 shares during the last quarter. Lombard Odier Asset Management Switzerland SA boosted its stake in shares of Thermo Fisher Scientific by 8.4% in the 2nd quarter. Lombard Odier Asset Management Switzerland SA now owns 14,490 shares of the medical research company’s stock valued at $5,875,000 after purchasing an additional 1,128 shares during the last quarter. Caledonia Investments PLC increased its position in shares of Thermo Fisher Scientific by 11.5% during the second quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after buying an additional 11,500 shares during the period. Weaver Capital Management LLC bought a new position in Thermo Fisher Scientific during the third quarter worth $506,000. Finally, Heritage Investors Management Corp boosted its position in Thermo Fisher Scientific by 9.6% during the second quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock valued at $22,944,000 after acquiring an additional 4,971 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, COO Michel Lagarde sold 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total value of $18,668,480.00. Following the completion of the transaction, the chief operating officer directly owned 65,480 shares of the company’s stock, valued at $38,200,377.20. This represents a 32.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the sale, the executive vice president owned 18,731 shares in the company, valued at $11,238,600. This trade represents a 36.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 149,271 shares of company stock worth $86,507,282. 0.33% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, October 8th. Citigroup upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $580.00 to $660.00 in a report on Thursday, December 11th. Wells Fargo & Company increased their price target on Thermo Fisher Scientific from $635.00 to $675.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Finally, UBS Group increased their target price on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $621.70.

Thermo Fisher Scientific Trading Down 0.6%

Shares of Thermo Fisher Scientific stock opened at $616.97 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $579.34 and a 200 day simple moving average of $514.40. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $628.08. The company has a market capitalization of $231.80 billion, a P/E ratio of 35.64, a price-to-earnings-growth ratio of 4.08 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a share buyback plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.